Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 6894675, 8 pages
https://doi.org/10.1155/2017/6894675
Research Article

Histological and Pathological Assessment of miR-204 and SOX4 Levels in Gastric Cancer Patients

1Department of General Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 230022, China
2Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China

Correspondence should be addressed to Wenbin Wang; moc.361@65290022oahin and A-Man Xu; moc.361@uxnama

Received 16 August 2016; Revised 15 November 2016; Accepted 29 November 2016; Published 4 January 2017

Academic Editor: Atif A. Ahmed

Copyright © 2017 Xiao Yuan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Gastric cancer is one of the most common cancers and the efficient therapeutic methods are limited. Further study of the exact molecular mechanism of gastric cancer to develop novel targeted therapies is necessary and urgent. We herein systematically examined that miR-204 suppressed both proliferation and metastasis of gastric cancer AGS cells. miR-204 directly targeted SOX4. In clinical tissue research, we determined that miR-204 was expressed much lower and SOX4 expressed much higher in gastric cancer tissues compared with normal gastric tissues. Associated analysis with clinicopathological parameters in gastric cancer patients showed miR-204 was associated with no lymph node metastasis and early tumor stages whereas SOX4 was associated with lymph node metastasis and advanced tumor stages. In addition, miR-204 and SOX4 were negatively correlated in tissues from gastric cancer patients. Our findings examined the important role of miR-204 and SOX4 played in gastric cancer, and they could be used as candidate therapeutic targets for gastric cancer therapy.